Thornhill J, Gregor L, Pittman Q
Department of Physiology, University of Saskatchewan, Saskatoon, Canada.
Regul Pept. 1990 Oct 29;31(1):1-10. doi: 10.1016/0167-0115(90)90190-8.
Hemodynamic (blood pressure and heart rate) experiments were conducted in conscious and/or anesthetized male Sprague-Dawley (S.D.), heterozygous and homozygous Brattleboro rats given intravenous (iv) dynorphin A(1-13), arginine vasopressin (AVP), norepinephrine (HCl, (NE) or sterile saline before and 10 min after an iv bolus injection of a specific receptor antagonist. These receptor blockers (kappa receptor antagonist Mr2266, alpha adrenoceptor antagonist phentolamine HCl or the AVP-V1 receptor antagonist d(CH2)5Tyr-(Me)AVP were given in equimolar concentrations (15 nmol/kg iv). In all conscious S.D. groups, iv injection of AVP (60 pmol/kg), NE (12.5 nmol/kg) and dynorphin A(1-13) (60 nmol/kg) evoked significant increases in mean arterial pressure (MAP) associated with concomitant bradycardia. The hemodynamic responses to 'both' AVP and dynorphin A(1-13) were blocked if given subsequent to AVP-V1 administration but not following phentolamine or Mr2266 pretreatment. The pressor and bradycardic responses of conscious heterozygous and homozygous Brattleboro rats after iv AVP or dynorphin again were only blocked by the AVP-V1 receptor antagonist. Anesthetized heterozygous and homozygous Brattleboro rats again showed pressor responses following iv AVP, NE or dynorphin A(1-13) but with slight or no associated bradycardia. The rise in blood pressure with AVP 'and' dynorphin A(1-13) in these groups also was only blocked by the d(CH2)5Tyr(Me)AVP antagonist. The results indicate that the pressor responses of rats given intravenous dynorphin A(1-13) involve the interaction of AVP-V1 receptors and suggest a functional interaction of these two neuropeptides in the modulation of vascular tone.
在清醒和/或麻醉的雄性斯普拉格-道利(S.D.)大鼠、杂合子和纯合子布拉特洛伯勒大鼠中进行了血流动力学(血压和心率)实验。在静脉推注特定受体拮抗剂之前和之后10分钟,分别静脉注射强啡肽A(1-13)、精氨酸加压素(AVP)、去甲肾上腺素(HCl,(NE)或无菌生理盐水。这些受体阻滞剂(κ受体拮抗剂Mr2266、α肾上腺素能受体拮抗剂盐酸酚妥拉明或AVP-V1受体拮抗剂d(CH2)5Tyr-(Me)AVP)以等摩尔浓度(15 nmol/kg静脉注射)给药。在所有清醒的S.D.组中,静脉注射AVP(60 pmol/kg)、NE(12.5 nmol/kg)和强啡肽A(1-13)(60 nmol/kg)可引起平均动脉压(MAP)显著升高,并伴有心动过缓。如果在给予AVP-V1后再给予AVP和强啡肽A(1-13),其血流动力学反应会被阻断,但在酚妥拉明或Mr2266预处理后则不会。静脉注射AVP或强啡肽后,清醒的杂合子和纯合子布拉特洛伯勒大鼠的升压和心动过缓反应仅被AVP-V1受体拮抗剂阻断。麻醉的杂合子和纯合子布拉特洛伯勒大鼠在静脉注射AVP、NE或强啡肽A(1-13)后再次出现升压反应,但伴有轻微或无相关心动过缓。在这些组中,AVP和强啡肽A(1-13)引起的血压升高也仅被d(CH2)5Tyr(Me)AVP拮抗剂阻断。结果表明,静脉注射强啡肽A(1-13)引起的升压反应涉及AVP-V1受体的相互作用,并提示这两种神经肽在调节血管张力方面存在功能相互作用。